Big data, 24-hour precision medical care or will be implemented in 2020?

Recently, at the 2016 Intel Life Science Information Technology Forum, a bio-computing accelerator platform called GTX one emerged, sparking new insights into the industry's precision healthcare industry. The GTX one acceleration system, which maximizes the computational power of the FPGA through algorithmic innovation, is equivalent to compressing a supercomputer into a small box, and an FPGA accelerator card can achieve the computational performance of 60 high-performance Xeon Xeon CPU servers, greatly shortening the computational time of bioinformatics data. In fact, the biomedical industry is undergoing rapid growth through the combination of biological data and the healthcare industry. The Intel Precision Medical Partner Program (Intel Bioit Partners), which was launched in Beijing, is expected to complete a series of precision medical processes such as gene sequencing-medical analysis-to develop medical solutions in 24 hours by 2020.

　　Precision medicine and gene sequencing are in full bursts

In the next five years, the global precision medical market will grow rapidly, according to the Southwest Securities Research Report, the 2015 Global Precision medical Market size of nearly 60 billion U.S. dollars, 2015-2020 growth rate of 15%, is the pharmaceutical industry growth of 3-4 times, 2013 gene sequencing market size of about 4.5 billion U.S. dollars, The compound growth rate in 2013-2018 was 21.2%, while China and India had a compound growth rate of 20-25% in 2012-2017. From the point of view of medical technology, accurate medical treatment is inseparable from gene sequencing, which is closely related to each other. As for the rapid development of precision medical care on a global scale, it is mainly due to the following three major factors.

1, the policy of strong support. Last year, President Barack Obama announced in his 2015 State of the Union address that it will focus on supporting precision medical development, investing $215 million in database and genetic screening. In China, there are also frequent positive policies for precision medical care, and the Ministry of Science and Technology has even convened the national first Precision medical strategy Expert Meeting, which plans to invest 60 billion yuan in precision medicine 2030 years ago. The positive news of the policy has greatly stimulated the enterprises and medical institutions to invest in human and financial resources to develop precision medical care.

2, the rise of gene detection technology, greatly promote the rapid development of precision medicine. Compared with traditional medical technology, precision medicine is not only confined to the treatment of diseases, it has a higher accuracy and efficiency in reducing the incidence of disease and effectively preventing and treating patients ' condition.

3, with the continuous improvement of living income level, the people's concern for their own health is more and more high, especially for China is entering the aging population, the medical problem is becoming an increasingly important issue for the whole society, the demand for precision medical care is also rising.

　　Precision medicine is still going to be 9,981 difficult

However, in the whole country, the current development of precision medical treatment is not smooth sailing, in fact, the whole industry there are many pain points.

The first problem with precision medicine is the problem of data collection, for many users, their personal health information data is a confidential content, they do not want to disclose their health data to others. This poses some difficulties for precision medical care, which needs to be based on a large amount of data, and without these data bases, precision medicine is hard to pinpoint.

The second challenge is a cost challenge. This technique, which is similar to gene sequencing, has been significantly lower in cost than it was before, but at this stage it is still not reaching the level of popularity, and the vast majority of precision medical programs require high costs, which are hard to bear for smaller medical institutions. In addition, the price of drugs for gene detection and molecular targeting therapy is also expensive.

The third problem is that for doctors and many small and medium-sized medical institutions, if precision medicine becomes part of daily health care, these physicians need to have deep molecular genetics and biochemical skills that not only need to explain genetic test results, but also how this information corresponds to post-treatment or pre-prophylaxis. and convey this information accurately to the patient. A survey of doctors at the Peking Union hospital last year showed that doctors ' personal scores on genetics were only 2.1 points (4).

The fourth problem is the payment of precision medical care. It is also necessary to consider whether the price of precision medicine can be accepted by ordinary citizens. If most people can't afford precision medicine, then precision medicine will eventually be hard to reach the mass market. In addition, it is a critical step for health insurance to cover precision medicine.

The fifth challenge is how precision medical care distinguishes patients from the heterogeneity of a patient's population. Even if it is differentiated, there is a need to involve the pharmaceutical industry, how to develop targeted and even gene drugs for specific groups, it is not so easy, and the drug from the clinical to the application of many aspects also need to be considered.

And one of the most fundamental problems that precision medicine faces is actually the technology itself, how to make more accurate analysis of big data, and also need more efficiency to realize it. For example, in the most mature nipt field of gene testing, it faces many problems, such as precision, detection cycle, False yin, false yang phenomenon and so on, which is also a common problem faced by all countries in the world.

　　Industry is in urgent need of innovation and change, precision medical care only hope

In order to promote the gradual popularization of precision medicine, it is necessary to promote the level of medical technology of precision medical care, so as to solve the genetic sequencing of precision medicine, data analysis, differentiation of patient population heterogeneity problems, and precision medical treatment costs can gradually decline.

In the 2000, the first genome of mankind began, and genetic testing was rapidly reformed in the form of Moore's law, speeding up the process of individualized and precise medical use of genetic testing.

In 2015, in order to meet the needs of complex gene sequencing data processing and high performance computing capabilities, Intel launched the Xeon Phi Coprocessor, which provides up to 61 cores, 244 threads, and 1.2 trillion floating-point performance. But gene sequence analysis has the characteristics of high IO density and high computational density, and it needs special means other than conventional accelerating method.

In the 2016, precision Medicine entered the algorithmic phase, and efficient data analysis became more and more important, and it was one of the most essential and fundamental challenges facing precision medicine. Human and future biotech companies are launching the GTX one Bio-computing accelerator platform based on FPGA, which, to a certain extent, effectively solves this problem by greatly improving the comparison and analysis efficiency of genetic test samples through high-energy algorithms.

In terms of speed, the GTX one acceleration product enables non-invasive prenatal DNA detection (NIPT) data to be 100 times times more efficient than analysis. For example, the GTX one processor (FPGA chip) can record 8.6 million queries per second in a massive data dictionary of more than 2 billion entries (nearly 90GB of data, or more than 22 DVD data volumes). Queries up to 17 times times faster than a 20-core Intel Xeon E5 CPU running Redis (recognized as the fastest memory database).

At a cost, the GTX one system can compress a high-performance server with a 20-core Intel Xeon E5 CPU for 24 hours to be completed in half an hour. This not only greatly reduces the time cost of data analysis, but also greatly reduces the procurement and operational costs of server clusters. At the same time, the GTX one full-load power consumption of only 89W, is 20 intel Xeon E5 CPU Physical core server power consumption of 1/5, greatly reducing the operating costs.

In terms of efficiency, the GTX one processor also takes a big step forward in human precision medicine, which specifically addresses the concurrency and access bottlenecks of sequence alignment and mutation analysis algorithms, and targets FPGA high computational performance characteristics, fully considering the flow of each stage of the algorithm, and redesigned the core algorithm of bioinformatics analysis. Its optimized design even refines the number of DDR controller transactions that may be triggered by its visit, the time characteristics of the DDR3 particle's internal open page, and so on, enabling the GTX one processor to be in a dual-channel 8G onboard DDR3 memory, from the compressed mass of data records, maneuvers, A sequence fragment is positioned on a 3 billion-base-length genome only with a maximum of 4 visits.

However, the GTX one accelerator platform is only the first step towards a human precision medical strategy, and the new technology is being applied to data analysis such as genome, transcriptome, epigenetic, and continuously enrich the analytical applications on the GTX one accelerator platform. Only by increasing the power of high-energy algorithms and big data analytics can we truly improve the overall efficiency of the entire industry chain of genetic testing, significantly reducing the cost, time and precision of testing, and truly building big data health management solutions.

　　Future big data, will fully enter the era of precision medicine

From any angle, accurate medical treatment based on gene sequencing and big data will be the inevitable trend of future medical development.

First of all, precision medicine can greatly improve the effectiveness of treatment for patients, but also to provide more accurate medical services, this is the current level of medical development status, has a significant promotion. In addition, the advent of precision medical treatment can also reduce the side effects of some non-essential drugs.

Second, with the continuous improvement of precision medical technology, it can reduce the number of ineffective treatment tests, significantly reducing the duration of treatment. Most importantly, with the improvement of precision medical technology, the cost of it can be reduced, and the cost of medical care can be significantly reduced by reducing other treatment testing programs. Many traditional medical bills don't look high, but they actually waste a lot of medical resources.

Finally, from a health point of view, precision medicine can provide a more comprehensive health management program, whether from the condition of the prognosis to the treatment of the disease, precision medicine can more accurately grasp the user's condition, can help patients more comprehensive management of their health.

In general, precision medicine is still on the road of continuous exploration, enterprises and medical institutions hold the attitude of responsibility for life, can go further. Genetic testing is pinned to the dream of human precision medical care, will be in the near future full-scale human and universal, this field will also be the birth of many great biotechnology enterprises.

　　Liu Yan, Zen Road ponder Internet, public number: liukuang110

Big data, 24-hour precision medical care or will be implemented in 2020?